SST receptor 2 (SSTR2), the predominant SST receptor expressed by pancreatic α-cells in humans and rodents (Blodgett et al., 2015), can be antagonized by highly selective SSTR2 antagonists to fully or partially restore glucagon responses to hypoglycemia in rodent models of T1D (Yue et al., 2012; 2013; Karimian et al., 2013; Leclair et al., 2016; Farhat et al., 2022; GhavamiNejad et al., 2022) and in non-diabetic rats who are pre-exposed to recurrent hypoglycemia to generate a model of glucagon counterregulatory failure (Hoffman et al., 2021). This evidence concerns the gene SSTR2 and Hypoglycemia.